Fabre-Kramer

Go or no go? Covid-19 upstages US regulatory decisions
EP Vantage
Tue, 03/24/20 - 10:30 am
FDA
regulatory
Bristol-Myers Squibb
ozanimod
Esteve
E-58425
Fabre-Kramer
AstraZeneca
Imfinzi
Astellas
Vesicare
AbbVie
Neurocrine
Orlissa
Sanofi
MenQuadfi
opicapone
Acceleron
Reblozyl
Thrice-rejected antidepressant, decades in the making, up for FDA review (yet) again
Stat
Tue, 12/1/15 - 01:16 pm
antidepressants
gepirone
Fabre-Kramer
GSK
FDA
advisory panels